Biopharmaceutical News and Research

RSS

Preclinical data of Ocugen's OCU400 genetic modifier published in Nature Gene Therapy

Ocugen, Inc., a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced today the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases.

3 Mar 2020

New clinical trial uses universal natural killer cell approach to treat acute myeloid leukemia

A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will treat patients with relapsed or refractory acute myeloid leukemia using a novel universal natural killer cell approach.

27 Feb 2020

Advion’s parent company Bohui Innovation Biotechnology will acquire Interchim group

Advion Inc. today announces parent company Beijing Bohui Innovation Biotechnology Co., Ltd., has filed its intention to acquire Adchim SAS, the parent company of the Interchim group companies.

From Advion 27 Feb 2020

CQDM and GlycoNet collaborate to support innovative glycomics research in Canada

CQDM and the Canadian Glycomics Network (GlycoNet) are pleased to announce they have formed a strategic partnership to identify and co-finance biopharmaceutical research projects in glycoscience across Canada.

25 Feb 2020

Sartorius launches BioPAT Spectro for use with ambr systems and BIOSTAT STR

Sartorius, a leading international partner of the biopharmaceutical industry today introduced BioPAT Spectro, a Quality by Design tool for use with its ambr automated micro and mini bioreactor systems and with the single-use production bioreactors BIOSTAT STR.

From Sartorius 24 Feb 2020

DuPont Nutrition & Biosciences partners with microbiome specialist MRM Health

DuPont Nutrition & Biosciences today announced a collaboration with the MRM Health NV, a biopharmaceutical company, focused on the discovery and development of innovative therapeutics based on the human microbiome.

From DuPont 19 Feb 2020

Simplifying Progress: Sartorius sharpens its brand focus

New brand promise, new logo, new colors – Sartorius looks different today. A leading international partner of life science research and the biopharmaceutical industry, the company has revised its brand look.

From Sartorius 18 Feb 2020

New approach for organic synthesis may apply to drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery

12 Feb 2020

Blue Water Vaccines enters into agreement to develop Streptococcus pneumoniae vaccine with St. Jude

Blue Water Vaccines Inc., a biopharmaceutical company focused on creating transformative vaccines solving global health challenges, has entered into an exclusive worldwide license agreement for the development of a Streptococcus Pneumoniae vaccine with St. Jude Children's Research Hospital, the nation's leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases.

11 Feb 2020

On drug pricing, the President’s numbers are still off

During the 2020 State of the Union address, President Donald Trump zeroed in on prescription drug prices, arguing that his administration is "taking on the big pharmaceutical companies."

5 Feb 2020

PhoreMost announces two key appointments to strengthen leadership team

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.

From PhoreMost 3 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

Researchers identify novel cellular entry factor for AAV vector types

Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types--the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles--that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.

23 Jan 2020

Synthego adopts good manufacturing practices for highest-quality genome engineering for clinical applications

Synthego, the genome engineering company, today announced it has adopted Good Manufacturing Practice standards to provide academic and industry partners with high-quality reagents for use in clinical research and development.

From Synthego Corporation 23 Jan 2020

Horizon Discovery enters into licensing agreement with NGM for GS knockout CHO K1 cell line

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line to NGM Biopharmaceuticals, Inc..

From Revvity 22 Jan 2020

Enterprise Therapeutics publishes open access paper on novel approach to treat cystic fibrosis

Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of its first peer-reviewed paper.

21 Jan 2020

SITESEEKER to be used for Otsuka’s therapeutics discovery programs

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, in disease-relevant pathways nominated by Otsuka.

From PhoreMost 21 Jan 2020

Mayo Clinic launches Clinical Data Analytics Platform to improve the health of patients

Mayo Clinic announced the Clinical Data Analytics Platform as the first venture under the Mayo Clinic Platform, a strategic initiative to improve health care through insights and knowledge derived from data.

14 Jan 2020

Airway Therapeutics receives funding to advance BPD treatment

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the injury cycle of inflammation for patients with respiratory and inflammatory diseases, announced today the closing of a $15.5 million oversubscribed Series C financing round.

8 Jan 2020

Pancreatic cancer cells release signal to suppress immune system's attack on tumors

A key immune signal has a previously unknown role in turning off the immune system's attack on pancreatic cancer cells, a new study finds.